Next Health
- NAD IV Therapy
- Vitamin IV Therapy
- Ozone Therapy
- IV Therapy
- Hyperbaric Oxygen Therapy (HBOT)
New York, NY
Oxygen therapy in New York includes medical HBOT at wound centers tied to NYU Langone, Mount Sinai, NewYork-Presbyterian, and Memorial Sloan Kettering, mild hyperbaric at wellness clinics, EWOT studios, and supplemental oxygen services. Demand reflects a dense, diverse, and high-income patient base with strong demand for cash-pay specialty care.
Medical-grade HBOT has strong evidence for UHMS-approved indications (diabetic foot ulcers, radiation injury, CO poisoning, decompression sickness). Mild hyperbaric and EWOT in New York, New York have much weaker evidence and sit in the wellness category. New York State Department of Health's strict scope-of-practice and supervision enforcement shapes which clinics can bill insurance and which must operate cash-pay.
With oxygen therapy clinics on Regenerated.com in New York, patients can compare chamber pressure, medical director credentials, and whether the indication matches the evidence base.
Regulatory context
FDA clears hyperbaric chambers as Class II medical devices under 21 CFR 878.5550. FDA has approved hyperbaric oxygen therapy for 14 specific indications aligned with the Undersea and Hyperbaric Medical Society (UHMS). Use for those indications is evidence-based and generally covered by Medicare and commercial insurance when documentation supports medical necessity. Any use outside the 14 approved indications is considered off-label and is not FDA-approved. FDA issued consumer updates in 2013 and again in 2021 warning patients and providers against marketing HBOT for unapproved conditions such as autism, cancer, Alzheimer disease, and long COVID.
The New York Office of Professional Medical Conduct investigates physician advertising complaints under Education Law 6530. The New York State Department of Health licenses Article 28 facilities. CMS MAC National Government Services adjudicates Medicare HBOT claims. The New York Attorney General enforces Executive Law 63(12) and General Business Law 349 against deceptive medical advertising, and has pursued cases against clinics marketing unproven therapies.